Expression and its clinical significance of receptor tyrosine kinase EphB1 in gastric carcinoma

WANG Jian-dong,LI Guo-li,DONG Ying-chun,SHENG Zhen,MA Heng-hui,LU Guang-ming,ZHOU Xiao-jun

DOI: https://doi.org/10.3969/j.issn.1007-3639.2009.04.001

2009-01-01

Abstract:Background and purpose:The Eph family of receptor tyrosine kinases plays an important role in the development of the nervous and vascular systems, and may be involved in carcinogenesis, progression and prognosis of certain cancers. This study aimed to investigate the expression and clinical significance of EphB1 subfamily in gastric cancer.. Methods:Quantitative real-time reverse-transcriptase PCR was used to detect expression levels of EphB1 mRNA in 61 specimens of gastric carcinomas (normal mucosa and carcinoma tissue from the same patient) and 5 gastric cancer cell lines. Immunohistochemistry with a specific polyclonal anti-EphB1 antibody was conducted in 58 tissue specimens to investigate the expression and subcellular location in normal and gastric cancer cells. Results: EphB1 mRNA were differentially expressed in gastric cancer cell lines. Comparing with normal mucosa, EphB1 mRNA was up-regulated in 69% (42/61) and down-regulated in 15% (9/61) of the tested tumor samples. There was no difference in 16% (10/61) of the samples. The mRNA level of EphB1 was significantly related to gender, tumor size and lymph node metastasis (P=0.006, 0.04 and 0.039, respectively). The expression level of the EphB1 protein was not completely consistent with that of mRNA. Upand down-regulation were detected in 17% (10/58) and 45% (26/58) of the samples, respectively; and no difference was detected in other samples. The loss of EphB1 protein was positively related to the depth of invasion, stage and metastasis of tumor (P=0.039, 0.001 and 0.008). Conclusion:EphB1 may be a tumor suppressor in progression of gastric carcinoma, and a new marker for prognosis of gastric cancer, it may also serve as a new target for gene therapy.